林业发展局批准PROLIA和XGEVA的生物类比BILDYOSZ和BILPREVDAZ,以处理骨骼问题。 FDA approves BILDYOS® and BILPREVDA®, biosimilars for PROLIA and XGEVA, to treat bone issues.

林业发展局批准了两个生物类比,即BILDYOSZ和BILPREVDAZ,它们与PROLIA和XGEVA药物相似。 The FDA has approved two biosimilars, BILDYOS® and BILPREVDA®, which are similar to the drugs PROLIA and XGEVA. 这些新药治疗骨质疏松症以及与癌症有关的骨骼问题,有可能使美国病人更容易获得和负担得起关键治疗。 These new drugs treat osteoporosis and bone issues related to cancer, potentially making critical treatments more accessible and affordable for patients in the US. 它们是RANK的抑制剂,被认为安全和有效,具有与原药类似的副作用,包括疼痛和低钙含量的风险。 They are RANK ligand inhibitors and have been found to be safe and effective with similar side effects to the original drugs, including pain and a risk of low calcium levels.